Introduction
============

Stable chronic obstructive pulmonary disease (COPD) can be evaluated by means of standard spirometry in a large majority of patients. In fact, spirometry is the gold standard to diagnose and classify COPD patients, and the severity of the disease. When properly performed, spirometry is the most reproducible, standardized and objective way of measuring flow limitation. A correct spirometry manoeuvre, however, requires the ability to clearly understand the manoeuvre, the intellectual capacity to perform it, and the absence of clinical limitations which might prevent several maximal forced expiratory manoeuvres from being performed. It is relatively common to deal with subjects with disabled intellectual capacity, with language difficulties, or clinical situations that make the forced expiratory manoeuvres painful or may even preclude them (chest pain, coronary vascular disease, minimal efforts dyspnoea, etc) In such cases spirometry is a poor cost/benefit procedure. Other situations such as intubation or tracheotomy, or patients lying in bed also limit the application of standard spirometry.

Pulmonary heterogeneity is, together with airways obstruction, a cardinal feature in the functional impairment of COPD. Heterogeneity, mostly dependent of peripheral involvement, is seen to increase with the severity of the disease; therefore, volumetric capnography, a technique that basically explores regional distribution, can be expected to correlate with the severity of disease in COPD patients. Previous authors have outlined the good relationship between changes in volumetric capnography parameters and the severity of COPD ([@b10-copd-2-381]; [@b11-copd-2-381]; [@b20-copd-2-381]; and [@b12-copd-2-381]); however, the diagnostic value of volumetric capnography has not been systematically explored. Recent studies reduce the intrinsic variability of the parameters, either by using internal relationships ([@b16-copd-2-381]), a procedure that reduces the noise-to-signal ratio, or by using the reference values reported by [@b1-copd-2-381] in normal people.

Volumetric capnography parameters are measured in continuous scales. Their use as a diagnostic test requires the selection of a cut-off value in the original scale in order to define positive and negative test outcome. Comparison of the dichotomised test results with the clinical status of the patient, evaluated as the disease stage from Global Initiative for Chronic Lung Disease (GOLD) classification (a spirometry based criterion) ([@b5-copd-2-381]), allows estimation of the test's diagnostic sensitivity (Se) and specificity (Sp), and determines the cut-off values that concurrently optimise Se and Sp. According to the hypothesis that volumetric capnography could be an alternative test to determine the amount of functional involvement in COPD patients, we have designed a study to compare the diagnostic value of volumetric capnography with spirometry as gold standard.

Methods
=======

### Subjects

A group of 84 patients (18 women, 66 men; age 60 ± 13 years, mean ± standard deviation) with clinical symptoms of COPD have been selected from patients attending the Pulmonary Function Laboratory. This protocol was approved by the Hospital's Research Committee. Patients were asked to give their consent for statistical use of the results of functional studies. The selection criteria were: clinical diagnosis of COPD based on clinical symptoms and history of exposure to cigarette smoking. Age limits were 30 to 80 years, and body mass index (BMI) was limited to 35. Exclusion criteria were cardiovascular comorbidity disease, sequelae of tuberculosis on the chest X-ray or any other coexistent lung disease, and neuromuscular or other diseases causing loss of ventilatory capacity. In order to exclude asthmatics, patients with a change of more than 12% in FEV~1~ after bronchodilator were excluded. Subjects were classified according to the Global Initiative for Chronic Lung Disease (GOLD) criteria ([@b5-copd-2-381]) into five groups: -- Group 0 (N = 33) or subjects at risk, with normal spirometry (FEV%FEC ≥70%, FEV~1~%pred ≥80%), but symptoms (cough, sputum).-- Group I (N = 1) or mild COPD, with FEV~1~%FVC \<70%, but FEV~1~%pred \<80%.-- Group II (N = 20) or moderate COPD, with FEV~1~%FVC \< 70%, and 50% ≤FEV~1~%pred \<80%.-- Group III (N = 19) or moderate to severe COPD, with FEV~1~%FVC \<70%, and 30% ≤FEV~1~%pred\<50%.-- Group IV (N = 18) or severe COPD, with FEV~1~%FVC \<70%, and FEV~1~%pred \<30%.

In these five groups FEV~1~ and FVC post-bronchodilator in percent of predicted were considered. A group of 14 normal subjects (6 women, 8 men; age 48 ± 11 years, mean ± SD), ex-smokers (more than 10 years of cessation) but free of symptoms was also studied, and is called "Ex-Smok" Group. The same exclusion criteria were applied. Table [1](#t1-copd-2-381){ref-type="table"} shows the descriptive and spirometric data for the different groups. All COPD subjects were in a stable situation, with no changes in respiratory symptoms during the month prior to the study, and no acute episodes of respiratory failure more than six months. Patients were asked not to have any inhaled therapy in the previous twelve hours. They sat down for at least half an hour before the procedure.

### Instrumentation

The equipment used was a Cosmo Plus System (Novametrix Medical Systems Inc, Wallinford, CT, USA), which measures CO~2~ concentration by means of a mainstream infrared cell, and airflow by an integrated pitot type pneumotachograph. Optical CO~2~ calibration and zero flow were performed before each measurement. The instrumental dead space (mouthpiece plus pneumotachograph and infrared cell chamber) was 18 ml. Pneumotachograph linearity was confirmed in the experimental range of flows, with increasing static flows measured by means of a rotameter (Collins, Braintree, Mass, USA). Expiratory flow and volume are expressed in BTPS conditions. Response characteristics of mainstream capnograph, as well as the validity of optical calibration, was determined by flowing a gas mixture containing 5% (in) or 0% (out) CO~2~ in air by means of a syringe at step changing flow rates in the range of the physiological rates. Delay between flow and capnographic signal and capnograph time constant were determined by analyzing the system's step response between 5% and 0% CO~2~ in air. In all cases delay was measured as the time elapsed between the beginning of flow transition according to the pneumotachographic recording, and the breakpoint of the capnographic recording. Average delay was 58.9 ± 16.2 ms. Time constant was determined as the time to reach 63.2% of the total step response, and was 24.4 ± 2.35 ms. Capnographic signal was time shifted according to the time delay.

**Measurements:** Capnographic recording was always performed before spirometry. Subjects were sitting during the recording procedure, breathing through a mouthpiece and with a nose clip. After two to three minutes of stable breath, CO~2~ and flow signals were continuously recorded for two more minutes, digitalised at sampling frequency of 100 Hz and stored in magnetic media. Forced spirometry was performed with patient in standing position by means of a Fleisch pneumotachograph (GS-System, Collins, Braintree, MA, USA) according to ATS/ERS Standardization of Spirometry (ATS/ERS, <http://www.thoracic.org/sections/publications/statements/pages/pfet/pft2.html>, update 2006). Spirometry was processed by GS software, and results expressed in BTPS conditions. To accept spirometry results, at least three manoeuvres with a reproducibility of 5% and a difference between the best and second best FEV~1~ and FVC below 150 ml had to be recorded. A maximum of eight forced expiratory manoeuvres were performed. Maximal values of forced expiratory flow in one second (FEV~1~), Forced Vital Capacity (FVC) and Maximal Mid Expiratory Flow between 25 and 75% of FVC (MMEF) were retained. The minimum time between manoeuvres was three minutes (of longer if requested by the patient). Spirometric manoeuvres were repeated 15 minutes after inhalation of 400 μg of salbutamol by means of a spacing chamber. According to recorded observations, time consumption by spirometric tests oscillated between about 20 minutes (the fastest) and 50 minutes (the slowest) plus the time consumed by the reversibility test. Predicted spirometric values were calculated from age, height and sex according to [@b14-copd-2-381].

Volumetric capnography parameters: A recording containing a minimum of fifteen complete breathing cycles, at a minimal tidal volume of 150 ml was processed for every patient. Every cycle was identified from the pneumotachographic signal, isolated and analysed separately by a computer procedure. Cycles not accepted for measurements were those with a P~ET~CO~2~ 5 mmHg lower or higher than the average P~ET~CO~2~. Also discarded were cycles with a tidal volume above or below 25% of average V~T~. Final results give the average of the measurements done on seven to fifteen cycles for each patient.

**End tidal CO**~***2***~ **fractional concentration (F**~**ET**~**CO**~***2***~**)**: to avoid the artefact of cardiac oscillations, F~ET~CO~2~ was measured on the CO~2~ elimination (VCO~2~) versus expired volume (V) curve \[VCO~2~ = ∫F~E~CO~2~·dV\], as the linear slope between expired volume and VCO~2~ of the segment defined by the end expiratory 10% of the total number of expiratory samples of each breath (Figure [1](#f1-copd-2-381){ref-type="fig"}). End-tidal partial pressure of CO~2~ (P~ET~CO~2~) was calculated from barometric pressure (P~B~) as: F~ET~CO~2~·(P~B~ -- P~H2O~).

*Bohr Dead Space (V~D~^Bohr^)* was calculated according to classical principles, assuming that end-tidal fraction of CO~2~ represents alveolar fractional concentration in the equation: $$\text{V}_{\text{D}}^{\text{Bohr}}/\text{V}_{\text{T}} = 1 - (\text{V}_{\text{E}}\text{CO}_{2}/\text{V}_{\text{T}})/\text{F}_{\text{ET}}\text{CO}_{2}$$where V~E~CO~2~ is the CO~2~ eliminated by breath.

*Pre-interface expirate (PIE)* was calculated according to Wolff and Brunner's method ([@b21-copd-2-381]). In short, the volume expired when CO~2~ has reached half of the end-expiratory value is doubled, the rest of the points are excluded from further analysis. Then the first derivative of the signal (dF~E~CO~2~/dV) is plotted against the volume, and the mean of this normalized distribution function is calculated. The volume at which this mean value is obtained represents the minimal mean volume of the convective airways, also called the pre-interface expirate or PIE ([@b21-copd-2-381]). Physiologically speaking, PIE represents the expired volume at which the interface between airways and alveolar gas is appreciated at airways opening.

**Phase III slope (Sl**~**III**~ **):** the curve between PIE and V~T~ is divided into four segments. According to [@b1-copd-2-381], Sl~III~ was calculated as the slope of the linear regression between F~E~CO~2~ and Volume for the two central segments.

**Series dead space (V**~**D**~ **^ser^):** The curve was corrected for the Sl~III~ between PIE and end tidal volume. From the corrected new curve, serial dead space volume (V~D~ ^ser^) was calculated by the equal area method. This procedure prevents overcorrection of phase II ([@b1-copd-2-381]). Airways dead space (V~D~ ^aw^) was obtained by subtracting Instrumental Dead Space (18 ml) from V~D~ ^ser^.

**Index of Alveolar Inhomogeneity (IAH):** According to previous studies ([@b10-copd-2-381]; [@b16-copd-2-381]) the difference between V~D~ ^ser^ and V~D~ ^Bohr^ is mainly due to impairment of regional distribution, which distorts the curve beyond PIE. An index of heterogeneity was calculated by relating both magnitudes according to: $$IAH(\%) = \left\lbrack {1 - \frac{\left( {V_{T} - V_{D}^{Bohr}} \right)}{\left( {V_{T} - V_{D}^{ser}} \right)}} \right\rbrack \times 100$$

**Index of Ventilatory Efficiency (IVE):** Alveolar exhaled volume or V~AE~ was determined from the VCO~2~ versus expired volume or VCO~2~(V) curve, according to previous studies ([@b15-copd-2-381]; [@b3-copd-2-381]). In short, after the linear fitting of the last end-expiratory segment previously described, the slope of this curve was decreased by 6% by pivoting on the end expiratory point. The new straight line crosses the VCO~2~(V) curve at a single point. The volume between this and the end-expiratory point corresponds to V~AE~ (Figure [2](#f2-copd-2-381){ref-type="fig"}). This volume tends to decrease as serial contamination of alveolar gas, heterogeneity, and phase II increase. As V~AE~ directly depends on V~T~ and V~D~ ^ser^, it seemed appropriate to express it in relation to these magnitudes. An index of ventilatory efficiency (IVE) has been calculated as follows: $$IVE(\%) = \frac{V_{AE}}{V_{T} - V_{D}^{ser}} \times 100$$We used a 6% change in end tidal slope of VCO~2~(V) curve rather than the 5% used in previous studies in ventilated patients, because we have observed less variability in spontaneously breathing patients when using 6% (CVar% ± SD: 9.14 ± 3.34, and 10.98 ± 4.16 at 6% and 5% respectively. N = 16 patients, twenty consecutive cycles each).

**Statistical analysis:** tests of normality (Kolmogorof-Smirnof) and homogeneity of variances (Levene homocedasticity test) were applied to data prior to deciding which test to use to compare the groups identified according to GOLD classification. For variables normally distributed, and with homogeneous variances, ANOVA analysis was performed. Tidal volume was added as covariant when necessary. If normality and homocedasticity tests failed at an error of 5%, the Kruskal-Walis rank test was applied to evaluate the differences between groups.

A multivariate model including Height, Body Mass Index, age, FEV~1~%pred, Tidal volume and MMEF%pred was used to determine the association of capnography parameters with functional data, and the possible confounding effect of factors relatively independent of respiratory functional abnormalities.

Receiver operating characteristic (ROC) curve analysis was performed to test the ability of each volumetric capnography parameter to detect the different levels of disease characterised by the GOLD Stages. The analysis was performed by cutting-off the population at increasing GOLD Stages of the disease. For each Stage Level, each parameter, considered as one-class classifier, was progressively increased or decreased in step values (threshold changes). Sensitivity (Se) and specificity (Sp) were calculated for each threshold change and expressed as a percentage. For each parameter at every stage ROC curves were constructed by plotting sensitivity against the false positive rate (100-specificity). The area under the curve (AUC) and confidence intervals at 95% were calculated to determine the degree and limits of accuracy of the curves, allowing paired comparisons. To determine cut-off points for each parameter at every stage, we calculated the point at which sensitivity equals specificity (Se = Sp). Positive and Negative Predicted Values were calculated using Bayes theorem ([@b6-copd-2-381]) based on COPD prevalence observed by [@b13-copd-2-381] at stages levels II, III and IV, and internal prevalence at stage 0. MedCalc^®^ and SPSS^®^ statistical packages were used for statistical analysis.

Results
=======

Table [2](#t2-copd-2-381){ref-type="table"} shows the descriptive statistics (mean, standard deviation) of capnography parameters in the COPD groups, as well as statistical data from ANOVA test. Variables ΔSl~III~ and IVE did not meet the criteria of homocedasticity, and the Kruskal-Wallis test was applied. Group I was excluded, because it had only one subject. Although no significant between groups difference was observed for V~T~, this parameter was used as covariant in the ANOVA analysis because of the documented tidal dependence of capnography variables ([@b1-copd-2-381]; [@b13-copd-2-381]), and the high dispersion of V~T~. In Table II values of F (or χ^2^) and P are given for between groups difference (F(χ^2^)~group~, and P~group~) and V~T~ covariant effect (F~cov~, and P~cov~).V~D~ ^aw^ showed no significant between-groups difference, but did show high dependence on V~T~. P~ET~CO~2~ showed mainly group, but also some V~T~ dependence. V~D~ ^Bohr^/V~T~ showed both group and tidal volume dependence. When corrected for predicted value, however, (Δ = real-predicted, ΔV~D~ ^Bohr^/V~T~) the covariant effect disappeared, but the group effect was maintained. Finally, IAH showed strong group but no V~T~ dependence.

Table [3](#t3-copd-2-381){ref-type="table"} shows the results of the multivariate linear regression. Significance P gives the probability associated to the rejection of the null hypothesis stating that the regression coefficient (Coeff) for a given independent variable is different from zero, at an alpha error below 5%. Variables in the equation (P \< 0.05) are marked in bold. The Beta statistic or regression coefficient for typified variables, allows a non dimensional comparison of the degree of association between dependent and independent variables. The narrowest association between FEV~1~%pred and capnography parameters was observed for IAH. This association was not confounded by other associations with the independent variables considered. In contrast, ΔV~D~ ^Bohr^/V~T~ showed some extra dependence on age, but its association with FEV~1~%pred was still high. ΔSl~III~ also showed a good correlation with FEV~1~%pred, but was greatly confounded by a high dependence on V~T~. Finally IVE was well defined by a model including FEV~1~%pred, MMEF%pred, and age.

Using capnography parameters as independent variables, FEV~1~% pred was well defined (R = 0.836) by a multivariate linear model including IAH and ΔV~D~ ^Bohr^/V~T~ (beta = −0.976, and 0.200 respectively) with the equation: $$\begin{array}{l}
{\textit{\textbf{FEV}}_{1}(\%\textit{\textbf{pred}}) = 112.08 - 5.60 \times \textit{\textbf{IAH}}} \\
{\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\, + 1.10 \times \Delta(\text{V}_{\text{D}}^{\text{Bohr}}/V_{T})} \\
\end{array}$$

Figure [3](#f3-copd-2-381){ref-type="fig"} shows the ROC curves constructed for 0, II, III and IV threshold stages of the disease at increasing values of IAH, Sl~III~, and ΔV~D~ ^Bohr^/V~T~, or decreasing values of IVE. Table [4](#t4-copd-2-381){ref-type="table"} shows the numerical analysis of the ROC curves, including AUC with 95% confidence intervals, the cut-off value at which sensitivity equals specificity, the value of sensitivity (or specificity) at this cut-off, positive predicted value (PPV), and negative predicted value (NPV) calculated either from internal prevalence at stage level 0, or from the cumulative prevalence calculated from [@b13-copd-2-381] for the remaining stage levels. A visual inspection of the ROC curves in Figure [3](#f3-copd-2-381){ref-type="fig"} shows that IAH and IVE seem more accurate than Sl~III~, and ΔV~D~ ^Bohr^/V~T~ to stage COPD patients. More precise information about the accuracy of capnography indices is obtained from numerical analysis of ROC curves. AUC, taken as a global summary statistic of diagnostic accuracy, shows higher values for IAH and IVE than Sl~III~, and ΔV~D~ ^Bohr^/V~T~, especially for diagnosis at low stage levels of the disease. Paired comparison between AUC showed the following differences with IAH: Sl~III~, and ΔV~D~ ^Bohr^/V~T~ at stages 0 and II; ΔV~D~ ^Bohr^/V~T~ and IVE at stage III; and ΔV~D~ ^Bohr^/V~T~ at stage IV. Sensitivity (and specificity) was similar and higher than 80% at all threshold levels for IAH, and IVE. In all cases PPV decreased with the threshold level of the disease, and the opposite was observed for NPV. The positive likelihood ratio (PLR) (ratio between the probability of observing the test result in diseased individuals, and the probability of observing the same result in non-diseased individuals) was globally high in IAH, followed by IVE, and ΔSLIII but only at stage IV.

Discussion
==========

According to our results, volumetric capnography parameters seem to be a good tool to determine the degree of functional involvement in COPD patients. It is generally considered that volumetric capnography reflects the degree of pulmonary regional homogeneity in relation to gas exchange ([@b21-copd-2-381]; [@b4-copd-2-381]; [@b9-copd-2-381]). From this point of view it seems reasonable to expect that volumetric capnography will reflect the progression of alveolar heterogeneity in parallel with that of the disease. Previous studies have shown some relationships between functional involvement in obstructive lung disease and specific indices obtained either from time based capnography ([@b19-copd-2-381]; [@b17-copd-2-381]; [@b22-copd-2-381]; [@b23-copd-2-381]) or from volumetric capnography in humans ([@b10-copd-2-381]; [@b11-copd-2-381]) and horses ([@b8-copd-2-381]). However, no systematic analysis of the diagnostic capabilities of volumetric capnography in COPD patients has been carried on until now in humans. Recent technical and conceptual advances have allowed anticipation of better perspectives for clinical applications of capnography.

On the volumetric capnography parameters
----------------------------------------

We have used classical (V~D~ ^Bohr^, Sl~III~) and newly developed parameters (VAE, PIE, V~D~ ^ser^), as well as combinations of both (IAH, IVE). Historically, the clinical use of volumetric capnography has been limited for several reasons, one of them being the lack of a reliable measurement of V~D~ ^aw^. The over-correction of phase II induces a phase III-dependent error in the classical, and most popular, equal area method. Nowadays, we can avoid this problem by taking into account the interface expired ([@b11-copd-2-381]; [@b1-copd-2-381]; [@b15-copd-2-381]). In fact, the finding that V~D~ ^aw^, calculated according to [@b21-copd-2-381], is unrelated to the disease stage in COPD supports this hypothesis.

Another factor that has limited the clinical use of volumetric capnography is the tidal dependence of the more usual capnography parameters. The use of predicted values means tidal dependence can be smoothed for V~D~ ^Bohr^ /V~T~, by subtracting the predicted value. A better result is obtained by using a common mode rejection ratio: IAH to completely eliminates the tidal dependence of V~D~ ^Bohr^ by referring it to V~T~--V~D~ ^aw^ ([Equation 2](#FD2){ref-type="disp-formula"}). IVE, based on the alveolar ejection volume (V~AE~) measured on the VCO~2~(V) curve, also uses V~T~--V~D~ ^aw^ as reference eliminate the tidal dependence of V~AE~. Both IAH and IVE parameters are related to functional troubles expressed during the alveolar phase of the capnogram. They are, therefore, physiologically related to regional distribution impairment as has been suggested by previous studies on normal subjects and COPD patients ([@b20-copd-2-381]; [@b9-copd-2-381]); however, the strong tidal dependence of Sl~III~ could not be corrected even after subtraction of the predicted value calculated from tidal volume.

In 1997 Kars et al observed a good correlation between the degree of airways obstruction and the V~D~ ^Bohr^ normalised at 1 L V~T~ (R = −0.66). Our results are in concordance with this observation, as ΔV~D~ ^Bohr^/V~T~ has shown a significant correlation with FEV~1~% pred. In the multivariate model we have used, however, age is significantly correlated with ΔV~D~ ^Bohr^/V~T~, a fact that was not noticed by [@b11-copd-2-381] in COPD patients, or by [@b1-copd-2-381] in normal subjects. In the study by Kars, only simple regressions were performed. Perhaps the age dependence we have observed is a surrogate dependence on the clinical evolution of the disease. Unfortunately, there is no way to verify this hypothesis from our present data.

ROC curves analysis
-------------------

In order to obtain an estimation of the diagnostic accuracy of each parameter, as well as to determine the cut-off for each stage level of the disease, we have performed a receiver operating characteristics (ROC) curve analysis. A reliable definition of the disease and a good estimation of its prevalence, are the key elements for using ROC curves with a high degree of statistical power. Clear guidelines for staging COPD patients have been published by the GOLD group. The staging process is based on spirometry, a completely standardised and reproducible technique, which leaves only a narrow margin for ambiguity. Prevalence data of COPD stages have been recently published by [@b13-copd-2-381]). Because their results are somewhat different from the internal prevalence calculated in our population, they have been used to obtain the cumulated prevalence for Positive and Negative Predicted Values and Likelihood Ratio calculations, except for Stage 0 level which does not represent a true prevalence of COPD disease, but simply a cut-off point for a reference population of ex-smokers (cessation for more than 10 years) with no clinical symptoms. Our population was not chosen to calculate the prevalence of COPD and that is why Stage Level 0 ROC Predicted Values and Likelihood Ratio do not correspond to the social prevalence of the disease. Furthermore, the stage-related variation of PPV and NPV may be influenced by their prevalence-dependence because we have used the cumulative prevalence in the ROC curve analysis. In contrast, sensitivity and specificity values, AUC and cut-off points, which are prevalence-independent are therefore valid for all stages, including stage 0.

The area under the ROC curve (AUC) is a global summary statistic of diagnostic accuracy. According to an arbitrary guideline (based on a suggestion by [@b18-copd-2-381]), it is possible to distinguish between non-informative (AUC = 0.5), less accurate (0.5 \<0.7 ≤0.9), highly accurate (0.9 \<AUC \<1) and perfect tests (AUC = 1). It has been recognised that AUC is equivalent to the probability that a randomly drawn individual from the positive reference sample has a higher (or lower) test value than a randomly drawn individual from the negative reference sample. As AUC gives equal weighting to sensitivity and specificity, we have considered the point at which specificity equals sensitivity as the cut-off point for all stages. However, other criteria could be used if we consider, for instance, the misclassification cost (False Positive and False Negative Cost, CFP and CFN respectively), which require quantification of the consequences of misclassification ([@b6-copd-2-381]). Without better information we have a priori considered that CFP = CFN, and we have given equal weight to sensitivity and specificity.

In a previous study [@b8-copd-2-381] studied the diagnostic value of volumetric capnography parameters in a population of horses suffering from recurrent airways obstruction (a veterinary equivalent of COPD in horses). In their study the best accuracy was obtained for V~D~ ^Bohr^/V~T~ (AUC = 0.70, Se = Sp = 63%) in the staging between without symptoms and with symptoms horses, equivalent to our stage 0 for which we have obtained nearly identical results using ΔV~D~ ^Bohr^/V~T~ (AUC = 0.68, Se = Sp = 63%). However practically all our AUC have been over 0.7.

In conclusion, capnography parameters seem to be useful for staging COPD patients when spirometry is difficult to perform because of technical or clinical constraints. Capnography is an easy-to-perform technique that requires no special effort or particular knowledge of the manoeuvre, and can be performed in severely disabled patients. It can be used as an alternative test to diagnose the severity of functional impairment in these patients. The Index of Alveolar Heterogeneity seems to be the best parameter for use in clinical practice.
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![Top: Expired volume and VCO~2~ sampled curves. Bottom: Measurements of end expiratory CO~2~ concentration. For detail please see the text.](copd-2-381f1){#f1-copd-2-381}

![Measurement of the volume of alveolar ejection (VAE) from the VCO~2~ versus expired volume curve. For detailed instructions, please see the text.](copd-2-381f2){#f2-copd-2-381}

![Receiver operating characteristics curve for each capnography parameter are plotted in separate boxes (ΔV~D~ ^Bohr^: Bohr dead space minus predicted value, ΔSl~III~: Slope of alveolar phase or phase III minus predicted value, IAH: Index of Alveolar Heterogeneity, IVE: Index of Ventilatory Efficiency). In every box, each curve corresponds to a different stage of the disease.](copd-2-381f3){#f3-copd-2-381}

###### 

Descriptive statistical data of the different groups of subjects studied

  **Group**   **N**   **Sex ♀/♂**   **Age yrs**   **BMI**       **FEV~1~ %pr**   **FVC %pr**   **MEF~50~ %pr**
  ----------- ------- ------------- ------------- ------------- ---------------- ------------- -----------------
  Ex-Smok     14      6/8           48 ± 11.1     24.2 ± 2.04   100.3 ± 8.9      93.2 ± 7.78   109.3 ± 14.7
  GOLD 0      26      13/13         52 ± 14.8     27.1 ± 4.37   86.3 ± 16.2      84.2 ± 17.3   67.8 ± 18.0
  GOLD I      1       0/1           57            32            88.6             98.5          42.9
  GOLD II     20      2/18          63 ± 11.4     26.5 ± 4.16   58.4 ± 7.32      73.5 ± 13.0   26.1 ± 8.2
  GOLD III    19      3/16          64 ± 13.1     25.5 ± 4.5    40.1 ± 5.73      59.2 ± 10.1   16.2 ± 7.8
  GOLD IV     18      0/18          62 ± 9.5      25.8 ± 4.49   22.4 ± 5.2       42.4 ± 14.9   7.42 ± 2.72

**Abbreviations:** BMI body mass index; FEV~1~%pr, forced expiratory volume at the first second in percent of predicted; FVC%pr, forced vital capacity in percent of predicted; MEF~50~%pr, maximal expiratory flow at 50% FVC in percent of predicted.

**Note:** Mean ± Standard Deviation.

###### 

Comparison of groups by ANOVA or Kruskal-Wallis test. VT is used as covariant in ANOVA test. Values of χ^2^ are marked with an asterisk

  **Group**   **N**   **STAT**         **V~T~ ml**   **V~D~^aw^ ml**   **P~ET~CO~2~ mmHg**   **IAH %**     **IVE %**     **V~D~^Bohr^/V~T~ %**   **Δ(V~D~^Bohr^/V~T~) %**   **ΔSl~III~ mmHg/L**
  ----------- ------- ---------------- ------------- ----------------- --------------------- ------------- ------------- ----------------------- -------------------------- ---------------------
  Ex-smok     14      mean ± SD        548 ± 209     115 ± 34          38.2 ± 3.76           4.62 ± 1.46   84.8 ± 8.16   32.0 ± 6.27             7.48 ± 4.25                12.78 ± 7.14
  GOLD 0      26      mean ± SD        530 ± 176     99 ± 23           34.2 ± 5.37           7.54 ± 2.81   70.0 ± 13.9   31.6 ± 4.50             7.40 ± 4.02                17.18 ± 9.05
  GOLD II     20      mean ± SD        697 ± 227     126 ± 38          31.4 ± 3.31           11.9 ± 3.30   51.5 ± 12.1   33.2 ± 5.94             10.45 ± 4.39               19.35 ± 11.57
  GOLD III    19      mean ± SD        572 ± 247     107 ± 37          33.5 ± 6.1            13.5 ± 2.57   48.0 ± 6.97   36.6 ± 6.72             11.82 ± 4.35               32.84 ± 26.9
  GOLD IV     18      mean ± SD        558 ± 205     117 ± 39          37.4 ± 7.08           17.5 ± 3.23   39.9 ± 6.5    40.9 ± 6.76             15.43 ± 5.33               40.46 ± 44.5
  ANOCOVA             F(χ^2^)~group~   1.76          1.54              3.299                 45.79         *64.45*\*     12.28                   10.07                      36.59\*
                      P~group~         0.128         0.185             0.009                 \<0.0001      \<0.0001      \<0.0001                \<0.0001                   \<0.0001
                      F~cov~           \--           116.6             4.722                 0.761         \--           63.08                   4.40                       \--
                      P~cov~           \--           \<0.0001          0.032                 0.209         \--           \<0.0001                0.039                      \--

**Abbreviations:** V~T~, tidal volume; V~D~ ^aw^, airways dead space; P~ET~CO~2~, end-tidal CO~2~ partial pressure; IAH, index of alveolar heterogeneity; IVE, index of ventilatory efficiency; V~D~^Bohr^/V~T~, Bohr dead space ratio; Δ(V~D~ ^Bohr^/VT), V~D~ ^Bohr^/V~T~ ratio real minus predicted; ΔSl~III~, Slope of phase III real minus predicted.

**Note:** F~corr~ and P~corr~ are values corrected for V~T~ effect in ANOVA analysis.

###### 

Results of the multivariant analysis. Variables in the model are in bold

  **Parameter**    **Height T (Sig T) beta**   **BMI T (Sig T) beta**   **Age T (Sig T) beta**   **VT T (Sig T) beta**   **FEV~1~%pred T (Sig T) beta**   **MEF%pred T (Sig T) beta**   **R(multi)**
  ---------------- --------------------------- ------------------------ ------------------------ ----------------------- -------------------------------- ----------------------------- --------------
  IVE              −1.40 (0.164)               1.85 (0.067)             **−2.41 (0.018)**        −0.70 (0.48)            **2.78 (0.006)**                 2.82 (0.006)                  **0.825**
  −0.084           0.110                       **−0.159**               −0.042                   **0.379**               0.379                                                          
  IHA              1.38 (0.170)                −1.07 (0.29)             1.40 (0.16)              −0.31 (0.76)            **−14.4 (\<0.0001)**             −1.66 (0.099)                 **0.826**
  0.079            −0.061                      0.090                    −0.017                   **−0.826**              −0.218                                                         
  ΔV~D~^Bohr^/VT   0.050 (0.96)                −0.46 (0.64)             **2.15 (0.034)**         −1.74 (0.08)            **−4.57 (0.0003)**               0.80 (0.42)                   **0.560**
  0.004            −0.041                      **0.205**                −0.146                   **−0.436**              0.158                                                          
  ΔSl~III~         1.87 (0.06)                 0.87 (0.38)              0.084 (0.93)             **−6.44 (\<0.0001)**    **−6.33 (\<0.0001)**             0.63 (0.53)                   **0.683**
  0.155            0.066                       0.007                    **−0.483**               **−0.475**              0.112                                                          
  V~D~^aw^         1.54 (0.13)                 −0.078 (0.94)            1.46 (0.15)              **11.06 (\<0.0001)**    0.078 (0.94)                     0.519 (0.13)                  **0.748**
  0.115            −0.005                      0.098                    **−0.130**               0.005                   0.035                                                          

**Abbreviations:** V~T~, Tidal volume; V~D~ ^aw^, airways dead space; IAH, index of alveolar heterogeneity; IVE, index of ventilatory efficiency; Δ(V~D~ ^Bohr^/V~T~), V~D~ ^Bohr^/V~T~ ratio real minus predicted; ΔSl~III,~ slope of phase III real minus predicted.

###### 

Receiver operating characteristics analysis (internal pevalence)

                   **Stage (cut-off)**    **AUC (95% C.I.)**     **Cut-off (95% C.I.) sens = spec**   **PPV (range)**     **NPV (range)**
  ---------------- ---------------------- ---------------------- ------------------------------------ ------------------- -------------------
  IAH              Stage II               0.908 (0.884--0.982)   9.76 (9.43--10.1)                    91.1 (89.5--92.6)   82.9 (82.1--83.3)
  Stage III        0.908 (0.833--0.957)   11.9 (11.1--12.7)      70.7 (69.6--75.8)                    86.2 (81.5--92.3)   
  Stage IV         0.926 (0.855--0.969)   14.2 (13.6--14.9)      53.6 (53.3--59.0)                    95.8 (94.7--97.1)   
  IVE              Stage II               0.939 (0.873--0.977)   57.2 (55.6--58.7)                    89.5 (88.2--92.3)   83.3 (80.0--85.6)
  Stage III        0.879 (0.798--0.936)   50.6 (49.9--51.3)      68.2 (67.7--69.4)                    84.5 (67.6--69.1)   
  Stage IV         0.902 (0.826--0.952)   45.5 (44.2--46.7)      51.7 (50.0--51.9)                    95.7 (94.5--97.0)   
  ΔV~D~^Bohr^/VT   Stage II               0.788 (0.694--0.864)   9.6 (8.54--10.74)                    76.0 (72.0--78.7)   59.8 (62.2--59.6)
  Stage III        0.777 (0.683--0.855)   11.0 (9.26--12.8)      52.3 (51.8--65.5)                    74.5 (73.9--81.4)   
  Stage IV         0.816 (0.725--0.886)   12.4 (10.7--14.1)      35.1 (34.0--42.0)                    90.6 (88.3--96.2)   
  ΔSl~III~         Stage II               0.753 (0.656--0.834)   18.0 (16.9--19.1)                    74.7 (72.7--74.9)   58.1 (56.0--59.1)
  Stage III        0.841 (0.753--0.906)   21.1 (20.5--21.7)      63.5 (62.9--66.7)                    83.3 (84.1--83.0)   
  Stage IV         0.871 (0.788--0.930)   28.4 (25.5--31.3)      85.2 (75.0--82.5)                    80.6 (76.3--80.9)   
